Kenneth J. O’Byrne - Publications, H-index & Citations

Kenneth J. O’Byrne

Princess Alexandra Hospital

91H指数

1.2K论文数

4.9W被引数

收录论文 212

发表时间

A Randomized Phase 2 Trial of Nivolumab and Stereotactic Ablative Body Radiation Therapy in Advanced Non-Small Cell Lung Cancer, Progressing After First- or Second-Line Chemotherapy (NIVORAD)

International Journal of Radiation Oncology*Biology*Physics

IF0

2025-12-19

PREAI

Gargi Kothari; Kenneth J. O’Byrne; Chris Brown; Martin R. Stockler; Mariya Walker; Nicholas Hardcastle; Tomas Kron; Hien V. Le; Suzanne Kosmider; Laird Cameron; Louis Lao; Paul Mitchell; Shankar Siva

Frontline sigvotatug vedotin plus pembrolizumab vs pembrolizumab for non-small cell lung cancer with PD-L1 tumor proportion score ≥50%: phase III study design 一线sigvotatug vedotin plus pembrolizumab 与 pembrolizumab 治疗PD-L1肿瘤比例评分≥50%的非小细胞肺癌：III期研究设计

Future Oncology

IF2.6

2025-12-13

OAAI

Martin Reck; Shun Lu; Kenneth J. O’Byrne; Carlos Barrios; Dmitri Pavlov; Fabian Tay; Marcelo V. Negrao

A phase III placebo-controlled study of eftilagimod alfa plus pembrolizumab and chemotherapy in metastatic non-small cell lung cancer 一项关于eftilagimod alfa联合pembrolizumab和化疗治疗转移性非小细胞肺癌的III期安慰剂对照研究

FUTURE ONCOLOGY

IF2.6

2025-12-01

PREAI

O'Byrne, Kenneth; Esteban, Emilio; Lee, Cheen Leng; Hegmane, Alinta; Volovat, Constantin; Lo Russo, Giuseppe; Ziogas, Dimitrios; Atmaca, Akin; Sebastian, Martin; Majem, Margarita

Impact of PD-L1 on first-line osimertinib outcomes in EGFR-mutant NSCLC: real-world data from the AURORA25 study and meta-analysis PD-L1对EGFR突变型NSCLC一线奥希替尼疗效的影响：AURORA25研究真实世界数据与荟萃分析

Lung Cancer

IF4.4

2025-11-24

PREAI

Marliese Alexander; Malinda Itchins; Jonathan Felthun; Adnan Nagrial; Lauren J. Brown; Kenneth O’Byrne; Antony J. Mersiades; Brett G.M. Hughes; Lydia Warburton; Benjamin Y. Kong; Melissa Moore; Prunella Blinman; Samantha Bowyer; Timothy Clay; Tim Spelman; Benjamin J. Solomon; Steven Kao

A phase I study of the OX40 agonist BGB-A445 with or without tislelizumab, an anti–PD-1 monoclonal antibody, in patients with advanced solid tumors: dose-escalation results 一项关于OX40激动剂BGB-A445与或不与tislelizumab（一种抗PD-1单克隆抗体）联合治疗晚期实体瘤患者的I期研究：剂量递增结果

Cancer Chemotherapy and Pharmacology

IF2.3

2025-10-08

OAAI

Jayesh Desai; Sanjeev Deva; Bo Gao; Kunyu Yang; Kenneth J. O’Byrne; Meili Sun; Tianshu Liu; Tarek Meniawy; Xinmin Yu; Mark Voskoboynik; Diwakar Davar; Marco Matos; Shiangjiin Leaw; Tahmina Rahman; Xiaofei Qu; Hugh Giovinazzo; Xin Chen; Yan Dong; Daphne Day

Treatment-Free Survival Over 6 Years of Follow-up in Patients With Metastatic NSCLC Treated With First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in CheckMate 227 Part 1 一线Nivolumab + Ipilimumab与CheckMate 227化疗治疗的转移性NSCLC患者6年以上的无治疗生存率

Journal of Thoracic Oncology

IF20.8

2025-06-03

PREAI

Solange Peters; Meredith M. Regan; Luis G. Paz-Ares; Martin Reck; Hossein Borghaei; Kenneth J. O’Byrne; Julie R. Brahmer; John R. Penrod; Janice Li; LaRee Tracy; Yong Yuan; Judith Bushong; Adam Lee; Laura J. Eccles; Saurabh Ray; Suresh S. Ramalingam

Rearranged during transfection (RET) lung cancer - Update on targeted therapies 转染重排 (RET) 肺癌 - 靶向治疗进展

LUNG CANCER

IF4.4

2025-02-01

PREAI

Mullally, W. J.; O'Leary, C. G.; O'Byrne, K. J.

Pooled safety analysis and management of sotorasib-related adverse events in KRAS G12C-mutated advanced non-small cell lung cancer 合并安全性分析及sotorasib相关不良事件的的管理在KRAS G12C突变型晚期非小细胞肺癌中的应用

ONCOLOGIST

IF4.2

2025-01-23

OAAI

Skoulidis, Ferdinandos; Li, Bob T.; Hochmair, Maximilian; Govindan, Ramaswamy; Vincent, Mark; van der Wekken, Anthonie J.; Reguart Aransay, Noemi; O'Byrne, Kenneth J.; Griesinger, Frank; Nishio, Makoto; Lindsay, Colin; Reinmuth, Niels; Paulus, Astrid; Papakotoulas, Pavlos; Kim, Sang-We; Ferreira, Carlos Gil; Pasello, Giulia; Duruisseaux, Michael; Gennatas, Spyridon; Dimou, Anastasios; Mehta, Bhakti; Kormany, William; Nduka, Chidozie; Sylvester, Brooke E.; Ardito-Abraham, Christine; Wang, Yang; de Langen, Adrianus Johannes

6y update of 1L nivolumab plus ipilimumab (N plus I) in metastatic (m) NSCLC, including in Japanese pts, from CheckMate 227

ANNALS OF ONCOLOGY

IF65.4

2024-10-01

PREAI

Nishio, M.; Ramalingam, S. S.; Ciuleanu, T.; Caro, R. Bernabe; Mizutani, H.; Lee, J.; Audigier-Valette, C.; Sangha, R.; Urban, L.; Burgers, J. A.; Pluzanski, A.; Lee, K. Hyeong; Zurawski, B.; Schenker, M.; Peters, S.; Paz-Ares, L. G.; Borghaei, H.; O'Byrne, K. J.; Brahmer, J. R.; Gupta, R. G.; Bushong, J.; Li, L.; Yuan, Y.; Blum, S. I.; Reck, M.

Sotorasib long-term clinical outcomes in pretreated KRAS G12C-mutated advanced NSCLC: Pooled analysis from the CodeBreaK clinical trials Sotorasib在经治KRAS G12C突变型晚期NSCLC中的长期临床结局：来自CodeBreaK临床试验的合并分析

ANNALS OF ONCOLOGY

IF65.4

2024-09-01

PREAI

Skoulidis, F.; Li, B. T.; Hochmair, M. J.; Govindan, R.; Vincent, M.; Van der Wekken, A. J.; Reguart Aransay, N.; O'Byrne, K. J.; Girard, N.; Griesinger, F.; Nishio, M.; Hafliger, S.; Lindsay, C.; Reinmuth, N.; Paulus, A.; Papakotoulas, P.; Obiozor, C.; Nduka, C.; Wang, Y.; De Langen, A. J.

Sotorasib (960 mg or 240 mg) once daily in patients with previously treated KRAS G12C-mutated advanced NSCLC Sotorasib (960 mg或240 mg) 每天一次用于先前接受过KRAS治疗的晚期NSCLC患者G12C-mutated

EUROPEAN JOURNAL OF CANCER

IF7.1

2024-09-01

PREAI

Hochmair, Maximilian J.; Vermaelen, Karim; Mountzios, Giannis; Carcereny, Enric; Dooms, Christophe; Lee, Se-Hoon; Morocz, Eva; Kato, Terufumi; Ciuleanu, Tudor-Eliade; Dy, Grace K.; Parente, Barbara; O'Byrne, Kenneth J.; Chu, Quincy S.; De Castro Junior, Gilberto; Girard, Nicolas; Snyder, Wendy; Tran, Qui; Kormany, William; Houk, Brett; Mehta, Bhakti; Curioni-Fontecedro, Alessandra

BMS-986012 (anti-fucosyl-monosialoganglioside-1 [fuc-GM1]) with carboplatin plus etoposide plus nivolumab (CE/NIVO) as first-line (1L) therapy in extensive-stage small cell lung cancer (ES-SCLC): Interim analysis (IA) of a randomized phase II study BMS-986012（抗岩藻糖基单唾液酸神经节苷脂-1[fuc-GM1]）联合卡铂、依托泊苷和纳武利尤单抗（CE/NIVO）作为广泛期小细胞肺癌（ES-SCLC）的一线（1L）疗法：一项随机Ⅱ期研究的期中分析（IA）

ANNALS OF ONCOLOGY

IF65.4

2024-09-01

PREAI

Kalinka, E.; Bahce, I.; Navarro Mendivil, A. F.; Ready, N.; Chu, Q. S-C.; Sugawara, S.; Sibille, A.; Provencio Pulla, M.; Johnson, M. L.; Hiltermann, J. T. J. N.; Ciuleanu, T-E.; Dziadziuszko, R.; Santo, A.; Zhang, Y.; Liu, Y.; Sarmiento, R.; Tannenbaum-Dvir, S.; Ojalvo, L.; Wu, J.; O'Byrne, K. J.

Unraveling functionally distinct metabolic programs to predict immunotherapy response in non-small cell lung cancer (NSCLC)解析功能上不同的代谢程序以预测非小细胞肺癌（NSCLC）的免疫治疗反应

ANNALS OF ONCOLOGY

IF65.4

2024-09-01

PREAI

Kulasinghe, A.; Yan, R.; Quinn, S.; Falkenstein, B.; Monkman, J.; O'Byrne, K. J.; Chennubhotla, S. C.; Pullara, F.

KRYSTAL-7: A phase III study of first-line adagrasib plus pembrolizumab versus pembrolizumab alone in patients with advanced NSCLC with KRASG12C mutation KRYSTAL-7: 一线adagrasib联合pembrolizumab与单用pembrolizumab治疗KRASG12C突变的晚期NSCLC患者的III期研究

ANNALS OF ONCOLOGY

IF65.4

2024-09-01

PREAI

Garassino, M. C.; Janne, P. A.; Barlesi, F.; Spira, A. I.; Mok, T. S. K.; Hochmair, M.; O'Byrne, K. J.; Felip, E.; Kim, S-W.; Cappuzzo, F.; Naidoo, J.; Safadi, M.; Wamil, B.; He, J.; Reck, M.

ALKTERNATE: A Pilot Study Alternating Lorlatinib With Crizotinib in ALK-Positive NSCLC With Prior ALK Inhibitor Resistance ALKTERNATE: 一项在ALK阳性NSCLC中交替使用氯拉替尼和克唑替尼的初步研究

JTO CLINICAL AND RESEARCH REPORTS

IF3.5

2024-09-01

OAAI

Itchins, Malinda; Liang, Shirley; Brown, Chris; Barnes, Tristan; Marx, Gavin; Chin, Venessa; Kao, Steven; Yip, Po Yee; Mersiades, Antony J.; Nagrial, Adnan; Bray, Victoria; Peters, Geoffrey; Parakh, Sagun; Garg, Kavita; Li, Bob T.; Mckay, Matthew; O'Byrne, Kenneth; John, Thomas; Gill, Anthony J.; Molloy, Mark P.; Solomon, Benjamin J.; Pavlakis, Nick

Expression analysis of Fuc-GM1 ganglioside in first-line therapy for extensive-stage small cell lung cancer (ES-SCLC) with BMS-986012, nivolumab, and carboplatin-etoposide Fuc-GM1神经节苷脂在广泛期小细胞肺癌（ES-SCLC）一线治疗中BMS-986012、nivolumab和卡铂-依托泊苷的表达分析

ANNALS OF ONCOLOGY

IF65.4

2024-09-01

PREAI

O'Byrne, K. J.; Zhang, Y.; Ouyang, J.; Chou, W-C.; Chou, C-H.; Wu, J.; Adelakun, O.; Hollmann, T.; Zeng, J. A.; Corrella, L.; Metzler, M.; Green, C.; Sarmiento, R.; Lees, E.; Liu, Y.; Ojalvo, L.; Wu, B.

Lung cancer (internet-based) Delphi (LUCiD): A modified eDelphi consensus process to establish Australasian clinical quality indicators for thoracic cancer 肺癌 (基于互联网) Delphi (LUCiD): 改良的eDelphi共识流程，用于建立澳大利亚胸部癌症的临床质量指标

RESPIROLOGY

IF6.3

2024-08-13

OAAI

Nash, Jessica; Stone, Emily; Vinod, Shalini; Leong, Tracy; Dawkins, Paul; Stirling, Rob G.; Harden, Susan; Bolton, Alison; Mcwilliams, Annette; O'Byrne, Kenneth; Wright, Gavin M.; Brunelli, Vanessa N.; Guan, Tracey; Philpot, Shoni; Navani, Neal; Brims, Fraser

Glycan Profiling in Small Extracellular Vesicles with a SERS Microfluidic Biosensor Identifies Early Malignant Development in Lung Cancer SERS微流体生物传感器在小细胞外囊泡中的聚糖谱可识别肺癌的早期恶性发展

ADVANCED SCIENCE

IF14.1

2024-06-17

OAAI

Zhou, Quan; Niu, Xueming; Zhang, Zhen; O'Byrne, Kenneth; Kulasinghe, Arutha; Fielding, David; Moller, Andreas; Wuethrich, Alain; Lobb, Richard J.; Trau, Matt

The expression and role of the Lem-D proteins Ankle2, Emerin, Lemd2, and TMPO in triple-negative breast cancer cell growth Lem-d蛋白Ankle2，Emerin，Lemd2和TMPO在三阴性乳腺癌细胞生长中的表达和作用

FRONTIERS IN ONCOLOGY

IF3.3

2024-04-24

OAAI

Rose, Maddison; Burgess, Joshua T.; Cheong, Chee Man; Adams, Mark N.; Shahrouzi, Parastoo; O'Byrne, Kenneth J.; Richard, Derek J.; Bolderson, Emma

Poor patient outcome correlates with active engulfment of cytokeratin positive CTCs within cancer-associated monocyte population in lung cancer

CLINICAL & EXPERIMENTAL METASTASIS

IF3.2

2024-02-28

OAAI

Wiegmans, A. P.; Ivanova, E.; Naei, V. Y.; Monkman, J.; Fletcher, J.; Mullally, W.; Warkiani, M. E.; O'Byrne, K.; Kulasinghe, A.

研究方向